The phrase ‘head and neck cancers’ (HNC) refers to a heterogenous group of diagnoses1, 2, 3. Cancer Research UK4 ranks the head and neck as the eighth most prevalent cancer site nationwide, accounting for 3% of all new oncological referrals. Across the developed world, these are cancers of adulthood, with incidence generally peaking around the seventh decade of life and remaining high thereafter. Survival is on the rise, owing to research and modern technological advances5.
HNC treatment varies depending upon primary site and tumour characteristics3. Radiotherapy is integral to UK treatment. Three-dimensional conformal radiotherapy (3DCRT) has long been superseded by intensity-modulated radiotherapy (IMRT) for head and neck cancer treatment, though both modalities are utilised for HNC6, 7. IMRT provides greater protection of organs at risk (OARs), abundant in the head and neck region,...
Sign in to your account
Log in
This content is available to registered users only. Please sign in to continue.
If you are not yet registered, please create your account on www.sor.org and verify your membership status. Once your account has been set up, return here and sign in to access the content.
Set up your account